deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06265285

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Sponsor: Mayo Clinic

Conditions Advanced Esophageal Squamous Cell Carcinoma Advanced Renal Cell Carcinoma Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 Clinical Stage IIB Cutaneous Melanoma AJCC v8 Clinical Stage IIC Cutaneous Melanoma AJCC v8 Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8 Esophageal Carcinoma Gastroesophageal Junction Adenocarcinoma Hepatocellular Carcinoma Locally Advanced Urothelial Carcinoma Lung Non-Small Cell Carcinoma Malignant Solid Neoplasm Metastatic Colorectal Carcinoma Metastatic Cutaneous Melanoma Metastatic Esophageal Squamous Cell Carcinoma Metastatic Head and Neck Squamous Cell Carcinoma Metastatic Urothelial Carcinoma Recurrent Esophageal Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Renal Cell Carcinoma Stage III Renal Cell Cancer AJCC v8 Stage IV Colorectal Cancer AJCC v8 Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 Stage IV Renal Cell Cancer AJCC v8 Unresectable Cutaneous Melanoma Unresectable Esophageal Squamous Cell Carcinoma Unresectable Urothelial Carcinoma Urothelial Carcinoma
Interventions Home Health Encounter Nivolumab Patient Monitoring Questionnaire Administration
Updated 8 times since 2024 Last updated: Dec 3, 2025 Started: Apr 30, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Advanced Esophageal Squamous Cell Carcinoma and Advanced Renal Cell Carcinoma, this trial is actively recruiting participants. The trial is conducted by Mayo Clinic and has accumulated 8 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshotRecruiting~Jun 2025 – ~Nov 2025 · 5 months · monthly snapshotRecruiting~Nov 2025 – ~Jan 2026 · 2 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshotRecruiting

Change History

8 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting PHASE2

  2. Nov 2025 — Jan 2026 [monthly]

    Recruiting PHASE2

  3. Jun 2025 — Nov 2025 [monthly]

    Recruiting PHASE2

  4. Oct 2024 — Jun 2025 [monthly]

    Recruiting PHASE2

  5. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

▶ Show 3 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  2. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. Mar 2024 — Apr 2024 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mayo Clinic
Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations